Multiple myeloma with t(11;14)‐associated immature phenotype has lower CD38 expression and higher BCL2 dependence - Kitadate - 2021 - Cancer Science - Wiley Online Library
CD38 expression and function in NK cells. (A) Role of CD38 in the... | Download Scientific Diagram
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab | Leukemia
Cells | Free Full-Text | Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications - ScienceDirect
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
Double CD38−/CD138− negative multiple myeloma - ScienceDirect
Functional multi-omics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma | bioRxiv
Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
Frontiers | CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
CD38, A Target for Immunotherapeutic Approaches in Cancer
Comparison of CD38-Targeted α- Versus β-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model | Journal of Nuclear Medicine
CD38 directed therapies for management of multiple myeloma | ITT
ePosters - Inecalcitol Stimulates CD38 Expression in Multiple Myeloma and Acute Myeloid Leukemia Cell Lines
JCM | Free Full-Text | Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
Blood and Hematology - CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance MM cells express high levels of CD38, while CD38 is expressed at relatively low levels on
CD38, A Target for Immunotherapeutic Approaches in Cancer
Detect CD38 expression during anti-CD38 therapy – Caltag Medsystems
New Strategies for Targeting CD38 in Multiple Myeloma Take Root
Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients | Haematologica
Cells | Free Full-Text | CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents
Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients | Haematologica
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab | Leukemia
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes | SpringerLink
International Clinical Cytometry Society
Expression of CD38 in normal and malignant plasma cells.... | Download Scientific Diagram
Immunophenotyping in Multiple Myeloma and Others Monoclonal Gammopathies | IntechOpen
